Search results
Eli Lilly boss: UK planning laws 'impediment' to investing
BBC News· 5 days agoThe boss of the world's most valuable pharmaceutical company has told the BBC that the UK's planning...
Eli Lilly & Co (NYSE:LLY): Jim Cramer’s Best Weight Loss Stock Pick for 2024
Insider Monkey via Yahoo Finance UK· 4 days agoWe recently published a list of the 10 Stocks to Buy and Sell Before the Third Quarter 2024...
Novo, Lilly Fall After Biden Calls for Cheaper Obesity Drugs
Bloomberg via Yahoo Finance UK· 3 days ago(Bloomberg) -- Novo Nordisk A/S and Eli Lilly & Co. shares fell Tuesday after US President Joe Biden...
Why the weight-loss drug boom is just the beginning
LoveMONEY via Yahoo Finance UK· 1 day agoFind out how Ozempic, Mounjaro, and other medicines are helping to revolutionise weight loss around the world... and how much people are willing to pay...
Pharma Stock Roundup: FDA Nod to LLY's Kisunla, SNY's Dupixent Gets EU Nod for COPD
Zacks via Yahoo Finance UK· 7 hours agoEli Lilly (LLY) wins FDA approval for its Alzheimer's disease drug, Kisunla. (donanemab). Sanofi...
Bankers Investment Trust: Why TSMC is a safer bet than Nvidia | Trustnet
TrustNet· 1 day agoGlobal stock markets have become obsessed with a narrow group of winners, such as chipmaker Nvidia and obesity drug manufacturers Novo Nordisk and Eli & ...
A New Alzheimer’s Drug May Be the Most Effective One Yet
Time via Yahoo News UK· 2 days agoLilly is collaborating with Roche to make the test more available to doctors who can order it as a...
5 Top-Performing S&P 500 Stocks of 1H Set to Shine Further
Zacks via Yahoo Finance UK· 4 days agoThese stocks also have a double-digit expected earnings growth for the current fiscal year. Some...
New Drug Approved for Early Alzheimer’s
New York Times· 3 days agoThe drug, by Eli Lilly, is the latest in a new class of treatments that could modestly slow cognitive decline in initial stages of the disease but also...
FDA approves donanemab, Eli Lilly’s treatment for early Alzheimer’s disease
CNN via Yahoo News UK· 3 days agoThe US Food and Drug Administration on Tuesday approved donanemab, a monoclonal antibody designed to slow the progression of early symptomatic Alzheimer’s disease.